Yan Zhu1,2, Chao Xue3, Jihong Ou4, Zhijuan Xie4, Jin Deng4. 1. Department of Nephrology, The First Affiliated Hospital of University of South China, Hengyang, China. zymonica@126.com. 2. Department of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China. zymonica@126.com. 3. Department of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China. 4. Department of Nephrology, The First Affiliated Hospital of University of South China, Hengyang, China.
Abstract
BACKGROUND: L-carnitine is an amino acid derivative that is thought to be helpful for treating renal anemia in hemodialysis patients. However, the mechanism remains to be fully elucidated. METHODS: A literature search was performed on PubMed, Embase, and Cochrane Central Register of Controlled Trials to identify randomized controlled trials (RCTs) and conduct a meta-analysis for investigating the effect of L-carnitine in the treatment of renal anemia in participants receiving hemodialysis. RESULTS: A total of 18 eligible trials with 1090 participants were included in this study. L-carnitine can significantly increase plasma free L-carnitine levels (mean difference [MD]: 140.53, 95% confidence interval [CI] 102.22-178.85; P < 0.00001), decrease the erythropoietin responsiveness index (ERI; MD: -2.72, 95% CI -3.20 to -2.24; P < 0.00001) and the required erythropoiesis-stimulating agent (ESA) doses (MD: -1.70, 95% CI -2.04 to -1.36; P < 0.00001). However, the use of L-carnitine was not associated with a higher hemoglobin level (MD: 0.18, 95% CI -0.20 to 0.55; P = 0.35) and hematocrit level (MD: 1.07, 95% CI -0.73 to 2.87; P = 0.24). In subgroup analyses, the effects of L-carnitine supplementation on renal anemia in patients on hemodialysis were independent of the treatment duration and intervention routes. CONCLUSION: The present meta-analysis indicated that L-carnitine therapy significantly increased plasma L-carnitine concentrations, improved the response to ESA, decreased the required ESA doses in patients receiving hemodialysis, and maintained hemoglobin and hematocrit levels. L-carnitine supplementation should be supported in hemodialysis patients. However, the relationship between L-carnitine treatment and long-term outcomes is still unclear. Further high-quality RCTs are needed to verify our findings.
BACKGROUND: L-carnitine is an amino acid derivative that is thought to be helpful for treating renal anemia in hemodialysis patients. However, the mechanism remains to be fully elucidated. METHODS: A literature search was performed on PubMed, Embase, and Cochrane Central Register of Controlled Trials to identify randomized controlled trials (RCTs) and conduct a meta-analysis for investigating the effect of L-carnitine in the treatment of renal anemia in participants receiving hemodialysis. RESULTS: A total of 18 eligible trials with 1090 participants were included in this study. L-carnitine can significantly increase plasma free L-carnitine levels (mean difference [MD]: 140.53, 95% confidence interval [CI] 102.22-178.85; P < 0.00001), decrease the erythropoietin responsiveness index (ERI; MD: -2.72, 95% CI -3.20 to -2.24; P < 0.00001) and the required erythropoiesis-stimulating agent (ESA) doses (MD: -1.70, 95% CI -2.04 to -1.36; P < 0.00001). However, the use of L-carnitine was not associated with a higher hemoglobin level (MD: 0.18, 95% CI -0.20 to 0.55; P = 0.35) and hematocrit level (MD: 1.07, 95% CI -0.73 to 2.87; P = 0.24). In subgroup analyses, the effects of L-carnitine supplementation on renal anemia in patients on hemodialysis were independent of the treatment duration and intervention routes. CONCLUSION: The present meta-analysis indicated that L-carnitine therapy significantly increased plasma L-carnitine concentrations, improved the response to ESA, decreased the required ESA doses in patients receiving hemodialysis, and maintained hemoglobin and hematocrit levels. L-carnitine supplementation should be supported in hemodialysis patients. However, the relationship between L-carnitine treatment and long-term outcomes is still unclear. Further high-quality RCTs are needed to verify our findings.
Authors: Arduino Arduini; Mario Bonomini; Elaine J Clutterbuck; Michael A Laffan; Charles D Pusey Journal: Nephrol Dial Transplant Date: 2006-04-12 Impact factor: 5.992
Authors: Jolanta Pekala; Bozena Patkowska-Sokoła; Robert Bodkowski; Dorota Jamroz; Piotr Nowakowski; Stanisław Lochyński; Tadeusz Librowski Journal: Curr Drug Metab Date: 2011-09 Impact factor: 3.731
Authors: Valeria Saglimbene; Suetonia C Palmer; Jonathan C Craig; Marinella Ruospo; Antonio Nicolucci; Marcello Tonelli; David Johnson; Giuseppe Lucisano; Gabrielle Williams; Miriam Valentini; Daniela D'Alonzo; Fabio Pellegrini; Paolo Strippoli; Mario Salomone; Antonio Santoro; Stefano Maffei; Jörgen Hegbrant; Gianni Tognoni; Giovanni F M Strippoli Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240